A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
Public ClinicalTrials.gov record NCT03817424. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
Study identification
- NCT ID
- NCT03817424
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 31 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- VIB7734 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 12, 2018
- Primary completion
- Jul 19, 2020
- Completion
- Jul 19, 2020
- Last update posted
- Dec 12, 2024
2018 – 2020
United States locations
- U.S. sites
- 19
- U.S. states
- 10
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Viela Bio Investigative Site | Anniston | Alabama | 36201 | — |
| Viela Bio Investigative Site | Birmingham | Alabama | 35294 | — |
| Viela Bio Investigative Site | Los Angeles | California | 90022 | — |
| Viela Bio Investigative Site | Upland | California | 91786 | — |
| Viela Bio Investigative Site | Danbury | Connecticut | 06810 | — |
| Viela Bio Investigative Site | Fort Lauderdale | Florida | 33309 | — |
| Viela Bio Investigative Site | Hialeah | Florida | 33016 | — |
| Viela Bio Investigative Site | Jacksonville | Florida | 32216 | — |
| Viela Bio Investigative Site | Miami Lakes | Florida | 33014 | — |
| Viela Bio Investigative Site | St. Petersburg | Florida | 33710 | — |
| Viela Bio Investigative Site | Lawrenceville | Georgia | 30046 | — |
| Viela Bio Investigative Site | Great Neck | New York | 11021 | — |
| Viela Bio Investigative Site | Charlotte | North Carolina | 28204 | — |
| Viela Bio Investigative Site | Durham | North Carolina | 27713 | — |
| Viela Bio Investigative Site | Duncansville | Pennsylvania | 16635 | — |
| Viela Bio Investigative Site | Philadelphia | Pennsylvania | 19104 | — |
| Viela Bio Investigative Site | Memphis | Tennessee | 38119 | — |
| Viela Bio Investigative Site | Allen | Texas | 75013 | — |
| Viela Bio Investigative Site | Mesquite | Texas | 75150 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03817424, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 12, 2024 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03817424 live on ClinicalTrials.gov.